Ionis Pharmaceuticals’ Tryngolza won a highly anticipated label expansion Wednesday, widening the market for a drug that’s is expected to become a blockbuster.
The Food and Drug Administration cleared Tryngolza as the first and only treatment to reduce levels of triglycerides and the risk of acute pancreatitis in people with a severe metabolic disorder. Tryngolza, which is already approved for a rare genetic condition known as familial chylomicronemia syndrome, or FCS, will now be sold to a larger population and inches Ionis closer to its 2028 breakeven goal.
“This represents our first launch into a highly prevalent disease and represents a paradigm shift for millions of people suffering from a risk of acute pancreatitis and cardiovascular disease due to very high triglycerides,” said Brett Monia, Ionis’ CEO, in an interview with BioPharma Dive ahead of the approval.
“It's a big step for the company, and it expands our wholly owned commercial pipeline to prevalent diseases,” Monia added.
Before the launch of Tryngolza, Ionis’ strategy was to license out drugs to partners such as Biogen and Novartis. But in 2024, Tryngolza became Ionis’ first wholly owned marketed drug. It’s an RNA-targeting therapy that blocks the production of the protein “apoC-III,” a key regulator of fat metabolism in the bloodstream.
The drug has had a successful launch, raking in $108 million in net sales last year and $27 million in the first quarter of this year. In 2025, Ionis landed another approval for a second wholly owned drug, Dawnzera, which has steadily generated revenue, pushing the company to achieve positive cash flow.
An extended approval of Tryngolza could bolster Ionis further.
The FDA approved the therapy in adults with severe hypertriglyceridemia, or sHTG, as an adjunct to diet to reduce triglyceride levels. It’s first treatment cleared by the agency to reduce triglycerides in tandem with acute pancreatitis in people with sHTG, and will be available in two doses given once a month via a self-administered autoinjector.
Based on the drug’s profile, Ionis “believes strongly Tryngolza will be the new standard of care ... for the management of severe hypertriglyceridemia, a disease that has a prevalence in the United States of more than 3 million people,” Monia said.
The label update comes with warning language noting potential increase in liver enzymes and to consider liver enzyme testing before dosing or an increase in dosage with Tryngolza. However, analysts largely believe this warning will not affect uptake.
The FDA “granted a label that we view as best case scenario,” wrote RBC Capital Markets analyst Luca Issi in a note to clients.
Ionis predicts peak annual net sales of the drug will exceed $3 billion. Multiple analysts expect the drug to be a commercial success, including Issi, who described Tryngolza as a “multi-billion dollar top-line” opportunity.
Approval was based on results from two Phase 3 trials in which the therapy met both of its primary goals. The therapy’s list price is set to $40,000.
While Ionis was historically viewed as a “platform monetization story," Tryngolza “gives the company its first potential multi-billion-dollar medicine and moves the story toward an independent commercial model,” Raymond James analyst Tiago Fauth wrote in his own note.
The competitive focus, Fauth added, now turns Arrowhead’s rival drug Redemplo, which should have data in sHTG this year. That will provide a clearer indication of Tryngolza’s “commercial opportunity.”
